Reneo Pharmaceuticals, Inc.

    Reneo Pharmaceuticals, Inc.

    NNASDAQ:RPHM
    - -
    USD
    - -
    - -
    Reneo Pharmaceuticals, Inc.
    NASDAQ:RPHM
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2019
    2020
    2021
    2022
    2023
    TTM
    USD
    - -
    - -
    - -
    - -
    - -
    - -
    Revenue per Share
    -1.6
    -0.8
    -2.19
    -2.12
    -2.52
    -1.69
    Basic EPS, GAAP
    -1.61
    -0.77
    -2.1
    -1.95
    -2.08
    -1.98
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -3.27
    -1.86
    -4.67
    -5.58
    -7.12
    -6.92
    Book Value per Share
    -2.97
    -1.74
    8.11
    4.08
    2.89
    2.29
    Tangible Book Value per Share
    8
    24
    18
    24
    31
    34
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    -12
    -19
    -40
    -52
    -77
    -57
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    22
    50
    148
    99
    88
    77
    Working Capital
    - -
    - -
    - -
    1
    1
    - -
    LT Debt
    -23
    -42
    147
    100
    89
    77
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    1
    1
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    33
    33
    33
    Market Capitalization
    475
    539
    507

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    Total Current Assets
    107
    84
    78
    Cash, Cash Equivalents & STI
    103
    83
    77
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    18
    3
    1
    Payables & Accruals
    14
    1
    1
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -11.36%
    Free Cash Flow
    - -
    - -
    33.95%
    Net Income, GAAP
    - -
    - -
    48.95%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.53
    -0.5
    -0.53
    -0.56
    -2.12
    2023
    -0.6
    -0.65
    -0.57
    - -
    -2.52
    2024
    -0.25
    -0.16
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

    • globenewswire.com

      Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

    • businesswire.com

      RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

    • globenewswire.com

      Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

    • globenewswire.com

      STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

    • prnewswire.com

      STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

    • globenewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of Shareholders

    • globenewswire.com

      STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

    • businesswire.com

      RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

    • prnewswire.com

      STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Reneo Pharmaceuticals, Inc. - RPHM

    • prnewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM

    • prnewswire.com

      Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure

    • businesswire.com

      RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

    • globenewswire.com

      Reneo Pharmaceuticals and OnKure Announce Proposed Merger

    • globenewswire.com

      Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results

    • globenewswire.com

      Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

    • zacks.com

      Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study

    • globenewswire.com

      Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

    • globenewswire.com

      Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

    • globenewswire.com

      Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences